Novartis patch gets approval at higher dose; I-Flow recalls delivery pump;

> The FDA has approved a higher dose of Novartis' Exelon Patch (transdermal rivastigmine) for the treatment of mild to moderate Alzheimer's disease. Press release

> While perhaps not the most instantly appealing route for drug delivery, Sophiris' PRX302, in development for benign prostatic hyperplasia, was well tolerated when dosed transrectally. Press release

> Coating drug-loaded particles with polyethylene glycol helps them ease further into the brain. Abstract

> I-Flow has recalled its ON-Q Pump with OnDemand Bolus Button, and the FDA says a malfunction in the device could lead to serious injury or death. Article

> Using microbubbles and ultrasound can disrupt the blood-brain barrier enough to get the cancer drug doxorubicin into rats' brains. Article | Abstract

> Arrowhead's ($ARWR) Calando Pharmaceuticals subsidiary has completed enrollment of its Phase Ib trial of CALAA-01, an RNAi therapeutic candidate targeting solid tumors. Press release

> Nordic NanoVector's Betalutin is slated to start clinical trials in non-Hodgkin's lymphoma in Sweden. Press release

> The T:slim pocket-sized insulin pump has started shipping in the U.S. Article

And Finally… Nanofactories could build drugs to order inside your body. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.